Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

Inclusion Criteria: * Diagnosed with plaque-type psoriasis defined by either: * A board-certified dermatologist, OR * Dermatology Nurse Practitioner, OR * Skin punch biopsy * Involvement of body surface area (BSA) \< 10% at screening and baseline visit. * The presence of plaque-type psoriasis at least two (2) plaques that are at least two (2) cm² in areas of the trunk, buttock, or extremities that are either: * Symmetrically located on contralateral body site OR * Within the same body site but separated by ≥ 1 cm * Able to give informed consent under IRB approval procedures Exclusion Criteria: * Known allergy or hypersensitivity to triamcinolone acetonide * Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study. * Inability to provide informed consent * Active untreated diseases or medication usage which may interfere with wound healing and immune function (anti-neoplastic, systemic immunosuppressants, anticoagulants, daily NSAIDS) * Use of tanning booths for at least 4 weeks prior to baseline visit * Current or recent use of topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to baseline visit * Current or recent use of systemic or biologic therapy for at least 4 weeks or 5 half-lives of the drug (whichever is longer) prior to baseline visit